| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/24/2013 | CN102743378B Composition containing 18 amino acids |
| 07/24/2013 | CN102727521B Preparation method of gentamycin bismuth carbonate capsule content intestinal release pellets |
| 07/24/2013 | CN102604118B Polyethylene glycol dendritic polymers and preparation method thereof |
| 07/24/2013 | CN102604032B Thermo-sensitive chain extender and polyurethane hydrogel with double sensitivity of temperature and pH |
| 07/24/2013 | CN102580093B Injection for preventing piglet diseases and preparation method thereof |
| 07/24/2013 | CN102552125B Injection composition containing oxiracetam and preparation method and application thereof |
| 07/24/2013 | CN102526536B An'erning medicinal composition buccal tablet and preparation method and application thereof |
| 07/24/2013 | CN102512686B Vaccine protectant, hydrophobia vaccine and preparation method thereof |
| 07/24/2013 | CN102499944B Nanometer silver antibiotic and antiviral compound liquid and its preparation method and products |
| 07/24/2013 | CN102417733B Preparation method of silk fibroin nanosphere |
| 07/24/2013 | CN102416181B Biodegradable high-polymer bonded photoactive Pt (IV) anticancer medicament micelle and preparation method thereof |
| 07/24/2013 | CN102309739B Chinese medicinal composition dispersible tablets |
| 07/24/2013 | CN102309579B Tarragon soup effervescent tablet and its preparation method |
| 07/24/2013 | CN102258785B Slow-release drug carrier |
| 07/24/2013 | CN102204882B Pharmaceutical composition containing ibuprofen |
| 07/24/2013 | CN102120773B Dual specificity antibodies and methods of making and using |
| 07/24/2013 | CN102120036B Nano micelle of biodegradable macromolecular-bonding Pt(IV) anti-cancer medicament and preparation method thereof |
| 07/24/2013 | CN102058898B Powder with antibacterial and haemostatic effects and preparation method and applications thereof |
| 07/24/2013 | CN102058560B Dihydromyricetin soft capsules and preparation method thereof |
| 07/24/2013 | CN102046150B Polymeric artificial tear system |
| 07/24/2013 | CN102014875B Formulation with reduced hygroscopicity |
| 07/24/2013 | CN101942022B Anti-human epidermal growth factor receptor single-chain antibody-ferritin heavy chain subunit protein and construction method and application thereof |
| 07/24/2013 | CN101934010B Plaster for treating rheumatic diseases |
| 07/24/2013 | CN101928458B Preparation method of multifunctional nanometer composite particle constructed by modified polymine |
| 07/24/2013 | CN101808637B Pharmaceutical composition |
| 07/24/2013 | CN101677602B Natural honey-containing compositions and method of preparation |
| 07/24/2013 | CN101669917B Scopolamine hydrobromide orally disintegrating microencapsule tablets based on NIMS system |
| 07/24/2013 | CN101669900B Polymeric delivery formulations of leuprolide with improved efficacy |
| 07/24/2013 | CN101631563B Lyophilized preparation comprising influenza vaccine, and method for preparation thereof |
| 07/24/2013 | CN101391103B Medicine composition for preventing and treating AIDS viral infection |
| 07/24/2013 | CN101384623B Process for the production of preformed conjugates of albumin and a therapeutic agent |
| 07/23/2013 | US8492538 Cyclodextrin derivative salts |
| 07/23/2013 | US8492444 Biogenic silica from silica-containing plant material such as rice hulls |
| 07/23/2013 | US8492366 E.g., salicylic acid, containing an alpha-hydroxy acid such as lactic, glycolic or citric acid |
| 07/23/2013 | US8492337 Targeted therapeutic proteins |
| 07/23/2013 | US8492330 Formulation comprising GLP-1 |
| 07/23/2013 | US8492081 Aldehyde-fixed, dried platelets with covalently attached exogenous active agent and method of making thereof |
| 07/23/2013 | US8491934 Stabilised prostaglandin composition |
| 07/23/2013 | US8491891 Human beta-glucuronidase mutants with elevated enzymatic activity under physiological conditions and method for identifying such |
| 07/23/2013 | US8491890 Methods and compositions for inhibiting diseases of the central nervous system |
| 07/23/2013 | CA2717679C Aqueous pharmaceutical compositions containing borate-polyol complexes |
| 07/23/2013 | CA2601011C Sugar-coated pill |
| 07/23/2013 | CA2569072C Preparation for localized delivery of therapeutic agent |
| 07/23/2013 | CA2544574C Stable vitamin b6 derivative |
| 07/23/2013 | CA2521961C Crosslinking of low-molecular weight and high-molecular weight polysaccharides; preparation of injectable monophase hydrogels; polysaccharides and hydrogels obtained |
| 07/23/2013 | CA2517439C Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| 07/23/2013 | CA2493878C Parenteral formulations containing a rapamycin hydroxyester |
| 07/23/2013 | CA2428114C Apolipoprotein analogues |
| 07/23/2013 | CA2377357C Fish serine proteinases and their pharmaceutical and cosmetic use |
| 07/18/2013 | WO2013106824A1 Epherin receptor targeting agents |
| 07/18/2013 | WO2013106766A2 THERAPEUTIC INDICATIONS OF miR-1291 |
| 07/18/2013 | WO2013106506A1 Stabilized pharmaceutical formulations of a potent hcv inhibitor |
| 07/18/2013 | WO2013106433A1 Cellulose derivatives for inhibiting crystallization of poorly water-soluble drugs |
| 07/18/2013 | WO2013106230A1 Otic formulations, methods and devices |
| 07/18/2013 | WO2013105895A1 A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
| 07/18/2013 | WO2013105894A1 A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
| 07/18/2013 | WO2013105856A1 Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| 07/18/2013 | WO2013105013A1 Mutant antibodies and conjugation thereof |
| 07/18/2013 | WO2013104995A2 Compositions and methods for treating viral infections |
| 07/18/2013 | WO2013104861A1 Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid) |
| 07/18/2013 | WO2013104399A1 Topical pharmaceutical compositions comprising bexarotene and a corticosteroids |
| 07/18/2013 | WO2013104067A1 Reducible self-assembled micelle drug delivery systems |
| 07/18/2013 | WO2013104050A2 Method for treating breast cancer |
| 07/18/2013 | WO2013073480A9 Cationic lipid having improved intracellular kinetics |
| 07/18/2013 | WO2013071457A4 Injectable veterinary composition for controlled, sustained release of ceftiofur and florfenicol in animal species, based on polyhydroxybutyrate hydroxyvalerate (phbv) microparticles |
| 07/18/2013 | WO2013071235A9 In-situ cross-linkable polymeric compositions and methods thereof |
| 07/18/2013 | WO2013020074A3 A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
| 07/18/2013 | WO2012175996A3 Drug delivery formulations |
| 07/18/2013 | WO2012140351A3 Caffeine and triacanthine composition for treating excess fat |
| 07/18/2013 | US20130184629 Skin treatment devices and methods with pre-stressed configurations |
| 07/18/2013 | US20130184453 Linear cyclodextrin copolymers |
| 07/18/2013 | US20130184435 Multi-drug ligand conjugates |
| 07/18/2013 | US20130184359 Processes for Extracting Colors from Hibiscus Plants |
| 07/18/2013 | US20130184358 Thixotropic compositions |
| 07/18/2013 | US20130184356 Chitosan composition |
| 07/18/2013 | US20130184354 Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management |
| 07/18/2013 | US20130184242 Pharmaceutical Composition for Topical Application |
| 07/18/2013 | US20130184237 Nitric oxide delivering hydroxyalkyl starch derivatives |
| 07/18/2013 | US20130184235 Hyaluronic acid derivatives containing groups able to release no |
| 07/18/2013 | US20130184216 Novel albumin-free factor viii formulations |
| 07/18/2013 | US20130183376 Hepatitis c virus liposome vaccine |
| 07/18/2013 | US20130183368 P97-antibody conjugates and methods of use |
| 07/18/2013 | US20130183363 Prevention of indwelling device related infection: composition and methods |
| 07/18/2013 | US20130183323 Targeted antibiotic and antimicrobial treatments for personalized administration |
| 07/18/2013 | US20130183319 Fgfr4 antibodies |
| 07/18/2013 | US20130183307 Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| 07/18/2013 | US20130183270 Orally Bioavailable Lipid-Based Constructs |
| 07/18/2013 | US20130183256 Silicone scar treatment preparation |
| 07/18/2013 | US20130183236 Mmp-targeted therapeutic and/or diagnostic nanocarriers |
| 07/18/2013 | US20130183234 Compositions Useful for Target, Detection, Imaging and Treatment, and Methods of Production and Use Thereof |
| 07/18/2013 | US20130180516 Self-contained Heating Unit and Drug-Supply Unit Employing Same |
| 07/18/2013 | CA2860973A1 A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
| 07/18/2013 | CA2860932A1 A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
| 07/18/2013 | CA2860914A1 Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| 07/18/2013 | CA2857400A1 Method for treating breast cancer |
| 07/18/2013 | CA2857207A1 Topical pharmaceutical compositions comprising bexarotene and a corticosteroide |
| 07/18/2013 | CA2832563A1 Multi-purpose lignin-carbohydrate binding system |
| 07/17/2013 | EP2615109A1 Localized pegylated modifications of exendin-4 analogs and use thereof |
| 07/17/2013 | EP2615099A1 Hydrous crystals of 2-o-alpha-d-glucosyl-l-ascorbic acid, powder containing hydrous crystals of 2-o-alpha -d-glucosyl-l-ascorbic acid, method for producing the hydrous crystals, method for producing the powder, use of the hydrous crystals, and use of the powder |
| 07/17/2013 | EP2614846A1 Embolic agent and preparation method therefor |